

10-year survival of a patient with metastatic prostate cancer: Case report and literature review

Krpina, Kristian; Markić, Dean; Rahelić, Dražen; Ahel, Juraj; Rubinić, Nino; Španjol, Josip

Source / Izvornik: **Archivio Italiano di Urologia e Andrologia, 2015, 87, 252 - 253**

Journal article, Published version

Rad u časopisu, Objavljena verzija rada (izdavačev PDF)

<https://doi.org/10.4081/aiua.2015.3.252>

Permanent link / Trajna poveznica: <https://urn.nsk.hr/urn:nbn:hr:184:711169>

Rights / Prava: [Attribution-NonCommercial 4.0 International/Imenovanje-Nekomercijalno 4.0 međunarodna](#)

Download date / Datum preuzimanja: **2025-03-16**



Repository / Repozitorij:

[Repository of the University of Rijeka, Faculty of Medicine - FMRI Repository](#)



10-year survival of a patient with metastatic prostate cancer: Case report and literature review

Kristian Krpina, Dean Markić, Dražen Rahelić, Juraj Ahel, Nino Rubinić, Josip Španjol

Department of Urology, Clinical Hospital Center Rijeka, Rijeka, Croatia.

Figure 2.

CT of the pelvis showing enlarged lymph nodes with dislocation of the bladder to the right side.




Figure 3.

Cystography showing bladder dislocation to the projection of right iliac bone.



Figure 4.

CT of the abdomen with no signs of disseminated disease.




Figure 5.

CT of the pelvis with no signs of disseminated disease and orthotopic position of the bladder.



REFERENCES

1. Jemal A, Siegel R, Xu J, Ward E. *Cancer statistics, 2010*. *CA Cancer J Clin*. 60:277-300.
2. Ferlay J, Shin HR, Bray F, et al. *GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10*. Lyon, France: International Agency for Research on Cancer; 2010, accessed on 12.12.2012. Available from: <http://globocan.iarc.fr>
3. Sylvester RJ, Denis L, de Voogt H. The importance of prognostic factors in the interpretation of two EORTC metastatic prostate cancer trials. European Organization for Research and Treatment of Cancer (EORTC) Genito-Urinary Tract Cancer Cooperative Group. *Eur Urol*. 1998; 33:134-43.
4. Montgomery RB, Goldman B, Tangen CM, et al. Southwest Oncology Group. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. *J Urol*. 2007; 178:1946-51.
5. Tangen CM, Faulkner JR, Crawford ED, et al. Ten-year survival in patients with metastatic prostate cancer. *Clin Prostate Cancer*. 2003; 2:41-5.
6. Eisenberger MA, Crawford ED, Wolf M, et al. Prognostic factors in stage D2 prostate cancer; important implications for future trials: results of a cooperative intergroup study (INT.0036). The National Cancer Institute Intergroup Study #0036. *Semin Oncol*. 1994; 21:613-9.
7. Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. *J Clin Oncol*. 2002; 20:3972-82.
8. Galsky M, Kelly WK. Use of nomograms for predicting survival in patients with castrate prostate cancer. *Urology*. 2003; 62 Suppl 1:119-27.